Stock AURA AURA BIOSCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Aura Biosciences, Inc.

Equities

AURA

US05153U1079

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
7.08 USD -0.28% Intraday chart for Aura Biosciences, Inc. +0.28% -20.09%
Apr. 15 Raj Parekh to Resign as Member of the Board of Directors of Aura Biosciences, Inc., Effective June 20, 2024 CI
Mar. 27 Aura Biosciences Shares Rise Following Q4 Results MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Raj Parekh to Resign as Member of the Board of Directors of Aura Biosciences, Inc., Effective June 20, 2024
CI
Aura Biosciences Shares Rise Following Q4 Results
MT
Aura Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Aura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
BU
Aura Biosciences to Participate in Upcoming Investor Conferences
BU
BTIG Cuts Aura Biosciences' Price Target to $21 From $38, Keeps Buy Rating
MT
Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial Evaluating the Safety and Efficacy of Belzupacap Sarotalocan for First-Line Treatment of Early-Stage Choroidal Melanoma
AQ
Arix Bioscience's Portfolio Company Doses First Patient in Late-stage Trial of Choroidal Melanoma Therapy
MT
Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial Evaluating the Safety and Efficacy of Belzupacap Sarotalocan (Bel-sar) for First-Line Treatment of Early-Stage Choroidal Melanoma
BU
Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial Evaluating the Safety and Efficacy of Belzupacap Sarotalocan (Bel-Sar) for First-Line Treatment of Early-Stage Choroidal Melanoma
CI
North American Morning Briefing : Stock Futures Hold Near Two-Month Highs
DJ
Aura Biosciences Insider Bought Shares Worth $1,434,987, According to a Recent SEC Filing
MT
Aura Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Aura Biosciences Reports Third Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights
BU
Aura Biosciences to Participate in Upcoming Investor Conferences
BU
Aura Biosciences Announces Pricing of Public Offering of Common Stock
BU
Aura Biosciences Announces Proposed Public Offering of Common Stock
BU
Aura Biosciences, Inc. Receives FDA Agreement Under Special Protocol Assessment for CoMpass Phase 3 Clinical Trial of Belzupacap Sarotalocan (Bel-Sar) in Early-Stage Choroidal Melanoma
CI
Aura Biosciences Gets FDA Agreement Regarding Phase 3 Clinical Trial of Bel-Sar
DJ
Aura Biosciences Receives FDA Agreement Under Special Protocol Assessment (SPA) for CoMpass Phase 3 Clinical Trial of Belzupacap Sarotalocan (Bel-sar) in Early-stage Choroidal Melanoma
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. AURA Stock
  4. News Aura Biosciences, Inc.